DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Fintepla is a drug marketed by Zogenix Inc and is included in one NDA. There are ten patents protecting this drug.
This drug has forty-nine patent family members in twenty countries.
The generic ingredient in FINTEPLA is fenfluramine hydrochloride. There are six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fenfluramine hydrochloride profile page.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be October 22, 2039. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
Summary for fintepla
|Finished Product Suppliers / Packagers:||1|
|Raw Ingredient (Bulk) Api Vendors:||24|
|Drug Prices:||Drug price information for fintepla|
|What excipients (inactive ingredients) are in fintepla?||fintepla excipients list|
|DailyMed Link:||fintepla at DailyMed|
DrugPatentWatch® Estimated Generic Entry Opportunity Date for fintepla
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
|Country||Patent Number||Estimated Expiration|
|Canada||3032996||Get Started for $10|
|Portugal||2991637||Get Started for $10|
|Japan||6655156||Get Started for $10|
|Australia||2020202655||Get Started for $10|
|South Korea||20170063851||Get Started for $10|
|Canada||2909335||Get Started for $10|
|Australia||2020267264||Get Started for $10|
|>Country||>Patent Number||>Estimated Expiration|